High-dose flu vaccine beneficial for older people with lung disease
The risk of being hospitalised for flu or pneumonia can be reduced with a high-dose flu vaccine for older people with chronic lung disease, according to the combined… read more.
The risk of being hospitalised for flu or pneumonia can be reduced with a high-dose flu vaccine for older people with chronic lung disease, according to the combined… read more.
The diabetes and weight loss injection semaglutide can reduce asthma attacks by up to 40 per cent according to research presented at the European Respiratory Society (ERS) Congress… read more.
Three large studies together show that, although the number of people who smoke is declining, people are taking up smoking at a younger age and vaping has increased,… read more.
In a third of cases, AI chatbots wrongly reassure sleep apnoea patients that their symptoms are not serious, discouraging them from seeking a referral to a specialist, according… read more.
NICE(UK) is unable to make a recommendation about the use in the NHS of brensocatib for treating non-cystic fibrosis bronchiectasis in people 12 years and over. This is because… read more.
Insmed Incorporated announced that Japan’s Ministry of Health, Labour and Welfare (MHLW) has approved Brinsupri (brensocatib 25-mg tablet), an oral, once-daily treatment for non-cystic fibrosis bronchiectasis (NCFB) in… read more.
Johnson & Johnson announced U.S. 510(k) regulatory clearance for MONARCH QUEST 3, the latest software update for the MONARCH Platform. The update reflects the company’s continued commitment to… read more.
A new study of sunscreens, baby lotions, shampoos, soaps, and other everyday products found that nearly all contained chemicals not disclosed on their labels. Most contained at least one unlabeled… read more.
Johnson & Johnson announced the first robotically-assisted bronchoscopy case in the Middle East using the MONARCH Platform. The procedure, which took place at the Cleveland Clinic Abu Dhabi,… read more.
Boehringer Ingelheim announced that the European Commission (EC) has granted marketing authorization for Jascayd (nerandomilast) for the treatment of adults with idiopathic pulmonary fibrosis (IPF) and adults with… read more.
AstraZeneca’s fixed-dose triple-combination Trixeo Aerosphere (budesonide/glycopyrronium/formoterol fumarate or BGF (320/28.8/9.6μg)) has been recommended for approval in the European Union (EU) for the maintenance treatment of asthma in patients… read more.
Cognitive function, hand dexterity, and breathing ability play an important role in helping people with chronic obstructive pulmonary disease (COPD) use their inhalers correctly, according to a new… read more.
If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.
You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.